AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|
11.3 C
New York
Monday, November 9, 2026

Tag: growth

Macroeconomic Global Outlook Report, Q2 2025 – Growth Forecast for 2025 Revised Down to 2.34% Amid Tariffs and Geopolitical Tensions

In its Q2 2025 update, the analyst lowers the global economic growth forecast to 2.34%, citing tariffs, trade policy uncertainties, and geopolitical tensions. Inflation is set to decrease globally but rise in the Americas and APAC. Central banks, including the ECB, are cutting rates. Business sentiments are down due to US tariffs. G20 trade shows growth, driven by US import hikes.
In its Q2 2025 update, the analyst lowers the global economic growth forecast to 2.34%, citing tariffs, trade policy uncertainties, and geopolitical tensions. Inflation is set to decrease globally but rise in the Americas and APAC. Central banks, including the ECB, are cutting rates. Business sentiments are down due to US tariffs. G20 trade shows growth, driven by US import hikes.

Australia Legal Cannabis Market Size, Share & Trends Analysis Report 2025-2030 | New Products and Rising Patient Adoption Fueling Expansion

The Australian legal cannabis market, valued at USD 123.9M in 2024, is projected to reach USD 540.6M by 2030, with a CAGR of 23.70%. Growth drivers include cannabis legalization, government initiatives, and new product launches. Market highlights: hemp dominates revenue, CBD leads the market, and industrial applications prevail. Explore comprehensive market insights, trends, and competitive strategies for informed decisions.
The Australian legal cannabis market, valued at USD 123.9M in 2024, is projected to reach USD 540.6M by 2030, with a CAGR of 23.70%. Growth drivers include cannabis legalization, government initiatives, and new product launches. Market highlights: hemp dominates revenue, CBD leads the market, and industrial applications prevail. Explore comprehensive market insights, trends, and competitive strategies for informed decisions.

Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025...

Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025...

Construction Global Industry Guide 2020-2029 | 2025 Edition Now Available

Explore the latest insights into the global construction industry with our comprehensive report. Discover market size, growth forecasts to 2029, and a breakdown of residential and non-residential segments. Analyze competitive pressures and key financials of top players, underpinning informed business strategies.
Explore the latest insights into the global construction industry with our comprehensive report. Discover market size, growth forecasts to 2029, and a breakdown of residential and non-residential segments. Analyze competitive pressures and key financials of top players, underpinning informed business strategies.

"Smart Moves: How CoreWeave’s Bold Acquisition Inspires Women to Invest with Confidence"

Hey, fabulous finance queens! 🌟 Buckle up because I've got the scoop on a major shakeup in the tech world that's like finding the...

Telecom Cloud Market worth $56,005.8 million by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The Telecom Cloud Market size will grow to USD 56,005.8 million by 2030 from USD 22,261.8...

Telecom Cloud Market worth $56,005.8 million by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The Telecom Cloud Market size will grow to USD 56,005.8 million by 2030 from USD 22,261.8...

Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer

The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic technologies and innovative therapies are expected to bolster market growth, though access issues remain crucial. Key players like Eton Pharmaceuticals, Antares Pharma, and Pfizer are leading with product innovation and strategic partnerships.
The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic technologies and innovative therapies are expected to bolster market growth, though access issues remain crucial. Key players like Eton Pharmaceuticals, Antares Pharma, and Pfizer are leading with product innovation and strategic partnerships.

Rakovina Therapeutics Congratulates Partner – Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award

Award Recognition underscores the importance of AI-driven drug discovery
Award Recognition underscores the importance of AI-driven drug discovery

DC Students to Get New Outdoor Adventure-Based Campus with $2M from Sunsetting Clark Foundation to Outward Bound School

Chesapeake Bay Outward Bound School and THEARC Partner to Launch Outdoor Campus in Southeast D.C. for Experiential Learning for Underserved Students  WASHINGTON, July 11, 2025...

MN8 Energy Successfully Closes $575 Million Senior Secured Notes Offering with Natixis Corporate & Investment Banking

Transaction Strengthens Capital Structure and Supports Continued Growth in Renewable Energy Portfolio NEW YORK, July 11, 2025 /PRNewswire/ -- MN8 Energy LLC ("MN8 Energy" or...

Truck Parking Club Accepts Strategic Investment from CAT Scale Company to Ramp Growth

Industry leader with nearly 50 years serving drivers supports marketplace solving critical truck parking shortage CHATTANOOGA, Tenn. and WALCOTT, Iowa, July 11, 2025 /PRNewswire/ --...

Identity Dental Marketing Recognized for Excellence in Dental Social Media Marketing

LAKEWOOD RANCH, Fla., July 11, 2025 /PRNewswire/ -- Identity Dental Marketing has been recognized as a leader in dental social media marketing and blogging services,...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGrowth